Our colleagues at Envisagenics recently announced their strategic multi-year collaboration with Boehringer Ingelheim to advance the development of next-generation oncology therapies. This partnership brings together Envisagenics’ SpliceCore platform for the discovery and validation of novel tumor-specific targets with Boehringer’s expertise in oncology drug development.

The agreement supports Boehringer Ingelheim’s oncology strategy of pairing bold modalities with novel, highly tumor-selective targets sourced through long-term partnerships. The collaboration builds on targets previously identified through Envisagenics’ proprietary SpliceCore® platform and will further validate their therapeutic potential across multiple therapeutic modalities, including antibody-drug conjugates (ADCs), T-cell engagers (TcEs) and multispecific antibodies. Upon successful completion of the research program, Boehringer Ingelheim will have the option to exclusively license selected targets for further development and commercialization.

Envisagenics is eligible to receive more than US$1 billion in potential payments, including an upfront payment, research funding, option fees and development, regulatory and commercial milestones, plus royalties on future product sales.

Learn more about the collaboration and the full announcement here.

Stony Brook Medicine’s Science and Research Awareness Series, better known as SARAS, celebrated its 22nd year this summer.n The Center for Biotechnology is a long-term supporter of the event as it speaks to our passion for helping to train the next generation of life sciences professionals.

Founded by Dr. Srinivas Pentyala, a professor and the director of translational research in the Department of Anesthesiology, SARAS is a three-week immersion into healthcare and biomedical research, built and staffed almost entirely by Stony Brook Medicine’s own physicians, nurses, researchers, and administrators. This year 125 high school students were given the opportunity to experience the “full arc of medicine”as Dr. Pentyala noted, and understanding that “the basic science, the translational science, how it is discovered… unless it is discovered or invented by someone, it cannot be translated in a clinic.”

Since its founding, SARAS has trained more than 4,000 high schoolers. Read more on this year’s program and the here.